Accelerate Diagnostics Tangible Book Value per Share
The Tangible Book Value per Share of Accelerate Diagnostics (AXDX) as of Sep 14, 2026 is -2.40 USD. In the previous year, Tangible Book Value per Share was -0.85 USD — a change of 181.78% (lower).
Get this data via API
Financial Data API
Tangible Book Value per Share
-2.40USD
YoY
181.78%
Last updated:
The Accelerate Diagnostics Tangible Book Value per Share history
3 Years
10 Years
25 Years
Max
| YEAR | Tangible Book Value per Share | YoY |
|---|---|---|
| -2.40USD | +181.78% | |
| -0.85USD | -10.67% | |
| -0.96USD | -36.52% | |
| -1.51USD | -44.17% | |
| -2.70USD | +751.23% | |
| -0.32USD | -112.91% | |
| 2.45USD | -52.24% | |
| 5.14USD | +54.29% | |
| 3.33USD | -41.53% | |
| 5.69USD | +102.15% | |
| 2.82USD | -71.36% | |
| 9.83USD | +108.33% | |
| 4.72USD | — |
Accelerate Diagnostics Stock analysis
Frequently Asked Questions about Accelerate Diagnostics stock
Tangible Book Value per Share of Accelerate Diagnostics is -2.40 USD in 2026.
Tangible Book Value per Share of Accelerate Diagnostics changed from -0.85 USD to -2.40 USD, representing a 181.78% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Tangible Book Value per Share Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.
Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.
Balance Sheet — Accelerate Diagnostics
All Key Metrics — Accelerate Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth